WW International (WW) Declined in Q3. Here’s Why

Kingdom Capital Advisors, a private investment firm, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the portfolio recovered from the significant drawdowns from November 2024 to June 2025. The composite returned 20.78% (net of fees) in the quarter, compared to 12.39% for the Russell […]

Fitch lowers Jefferson Health’s outlook: 4 things to know 

Philadelphia-based Jefferson Health’s outlook was lowered to negative from stable by Fitch.  Four things to know:  1. Jefferson Health reported a $196 million operating loss (-1.2%) operating margin in fiscal 2025, which ended June 30. The results include 11 months of Lehigh Valley Health Network activity. Jefferson and Allentown, Pa.-based LVHN merged on Aug. 1, […]

STAT+: Kailera Therapeutics, an obesity drug startup, raises $600 million

Investors announced one of the biggest private financing rounds of the year for a biotech company Tuesday, pouring $600 million into obesity startup Kailera Therapeutics.  Bain Capital’s private equity group led the financing, which also included Royalty Pharma and sovereign wealth funds in Canada and Qatar. Several of Kailera’s founding investors also put more money […]

The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa

For Immediate Release Chicago, IL – October 14, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. AAPL, Eli Lilly and Co. LLY […]

Pharmacological Approaches to the Treatment of Skeletal Muscle Aging

Researchers here provide a tour of better known pharmacological targets for the development of drugs to slow or potentially reverse loss of muscle mass and strength with age. The high bar to beat is the effects of resistance exercise, but there is likely merit in drugs that will enhance the improvements provided by resistance exercise, […]

BF Biosciences Launches Zeptide in Pakistan to Target Diabetes and Obesity

BF Biosciences Limited has announced the commercial launch of Zeptide® (Tirzepatide), a next-generation therapy for Type 2 diabetes and obesity, now available in Pakistan in a user-friendly, pre-filled syringe. The company, a trailblazer in Pakistan’s biopharmaceutical sector, disclosed the development in a notice to the Pakistan Stock Exchange (PSX) earlier today. Zeptide® contains Tirzepatide, a […]